The association of adiponectin with metabolic syndrome and clinical outcome in patients with non-diabetic chronic kidney disease

I-Ching Kuo,1,2,3 Ping-Hsun Wu2, Hugo You-Hsien Lin2,3, Sheng-Wen Niu2,3, Jiun-Chi Huang2,4, Chi-Chih Hung2*, Yi-Wen Chiu2*, Hung-Chun Chen2

1 Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, 2 Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, 3 Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, 4 Department of Internal Medicine, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

These authors contributed equally to this work.

* chichi@kmu.edu.tw (CCH); chiuyiwen@gmail.com (YWC)

Abstract

Adiponectin is the most abundant circulating adipokine, and it has insulin-sensitizing and anti-inflammatory properties. Although it has been speculated that kidney function decline associated with elevated adiponectin is attributable to decreased renal clearance and compensatory responses to adiponectin resistance, it is unclear how elevated adiponectin affects clinical outcomes in chronic kidney disease (CKD) patients and whether the effects are the same as those in the general population. Therefore, the aim of this study is to examine whether the association between serum adiponectin levels and clinical outcomes in non-diabetic CKD patients is independent of conventional risk factors, BMI, and metabolic syndrome components. We enrolled 196 non-diabetic CKD patients with eGFR ranging between 10 and 60 mL/min/1.73 m^2, these patients were divided into two groups based on the presence of metabolic syndrome. The primary endpoint was all-cause mortality or renal events (renal failure requiring renal replacement therapy [RRT] or 50% reduction in eGFR). During the mean follow-up period of 5 years, 48 (24.5%) incident cases of end-stage renal disease (ESRD) were observed, and 33 (16.8%) deaths occurred. The mean eGFR was 29.8 ± 12.8 mL/min/1.73m^2. The baseline median adiponectin concentration in the cohort was 29.4 (interquartile range, 13.3–108.7) μg/ml. Adiponectin levels were inversely related to body mass index (BMI) (r = −0.29; P < 0.001) and waist circumference (r = −0.35; P < 0.001). In the fully adjusted Cox regression model, the hazard ratios (HRs) were 2.08 (95% confidence interval [CI], 1.08–4.02; P = 0.03) for RRT and 1.66 (95% CI, 1.03–2.65; P = 0.04) for composite renal outcome. The risks remained consistent within different subgroups. However, no association was observed with mortality risk. In conclusion, higher adiponectin levels are associated with a higher risk of ESRD independent of conventional risk factors, BMI, and metabolic syndrome components.
Introduction

Adiponectin is the most abundant adipocyte-synthesized adipokine, circulating in the blood as various multimers, and is expressed at low levels in obese individuals. In contrast to the proinflammatory properties of most adipokines, adiponectin exhibits insulin-sensitizing, anti-inflammatory, anti-atherogenic, cardioprotective, and anti-oxidative stress effects[1–5]. Adiponectin levels are strongly determined by body composition and are mainly inversely associated with visceral fat, total body fat, body mass index (BMI), and waist circumference[6–10]. As visceral obesity, which often accompanies metabolic syndrome, is a risk factor for the onset and progression of chronic kidney disease (CKD), systemically circulating adipokines may be involved in the pathogenesis of CKD. Studies have indicated that in the general population, lower adiponectin levels are linked to insulin resistance, type 2 diabetes mellitus (DM), and coronary artery disease (CAD) [11–13], which are conditions that may contribute to CKD development.

Dysregulated metabolism of adipokines in the CKD population might be probably due to decreased renal excretion and the effects of chronic inflammation or protein-energy wasting (PEW). Adiponectin levels are markedly elevated with declining kidney function[14], and it possesses significantly negative correlation with eGFR[15–18] despite the presence of high cardiovascular (CV) risks and mortality. In fact, the clinical role of adiponectin is more complex because of varying disease circumstances and the multiplicity of metabolic pathways among CKD patients. Contrary to the beneficial effects of adiponectin in the general population, higher rather than lower adiponectin levels are associated with higher progression of kidney disease[19, 20]. Conflicting results have been obtained regarding the effect of adiponectin on CV outcomes and mortality across studies in the CKD population. High adiponectin levels are related to CV events and all-cause mortality in stage 3–4 CKD or HD patients [6, 21, 22], whereas some studies have found that the association is only dependent on BMI or waist circumference[7, 23]. Besides, as epicardial adipose tissue (EAT) thickness increases in CKD, secretion of adiponectin from EAT also plays the emerging role in cardiac metabolism regulating CV outcomes[24]. Moreover, the largest cohort study showed no significant association between longitudinal changes in adiponectin and mortality in HD patients[25].

The clinical significance of metabolic syndrome in CKD has been clarified; that is, metabolic syndrome is associated with hypoadiponectinemia, insulin resistance, and eGFR decline [10, 26]. In addition, clustering metabolic syndrome components increased the risk of rapid decline of eGFR in a gradual manner[27]. Based on the aforementioned reports, we conducted this cohort study to examine whether the predictive role of adiponectin in ESRD and all-cause mortality in non-diabetic patients with advanced CKD is independent of adiposity, especially BMI, and metabolic syndrome components.

Materials and methods

Participants and data collection

This observational study was conducted in the affiliated hospital of Kaohsiung Medical University in Southern Taiwan from January 2010 to June 2017. Patients aged between 20 and 85 years were initially screened from an integrated or traditional CKD care program which included various causes of pre-dialysis CKD. A total of 196 non-diabetic CKD patients with eGFR in the range of 10–60 ml/min/1.73m² were recruited. eGFR was determined using the four-variable Modification of Diet in Renal Disease (MDRD) formula, which is generally applied in the Taiwan National Database to assess CKD prevalence and dialysis initiation[28, 29]. Eligible patients were followed up for more than 3 months to confirm the presence of
CKD. Exclusion criteria were as follows: malignancy, liver disease, and active infectious disease. Demographic details, relevant medical history, blood pressure and anthropometric measurements (weight, height, and waist circumference) were recorded by trained nurses in the clinic at the time of enrollment. BMI was calculated as weight in kilograms divided by the square of height in meters (kg/m²). All participants provided written informed consent with the approval of the Kaohsiung Medical University Hospital Institutional Review Board (Institutional Review Board number: KMUH-IRB-990198), in accordance with the Declaration of Helsinki.

**Laboratory measurements**

Within 1 month of enrollment, blood and urine were sampled from patients after an overnight fast. Blood was drawn into EDTA tubes, centrifuged at 4°C immediately, and then stored at −80°C in aliquots until further analysis. The hemogram and biochemical parameters, including blood sugar, serum creatinine, albumin, HbA1c, phosphate, uric acid, total cholesterol, triglyceride (TG), low-density lipoprotein (LDL-C), high-density lipoprotein (HDL-C), C-reactive protein (CRP), and urine protein-to-creatinine ratio (UPCR) were measured using an automated analyzer following standardized procedures at the Department of Laboratory Medicine at Kaohsiung Medical University Hospital. According to the modified National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) criteria, metabolic syndrome was defined as the presence of three or more of the following components: (1) central obesity (waist circumference ≥ 90 cm in men or ≥ 80 cm in women, according to the ethnic criteria for Asians); (2) TG ≥ 150 mg/dL or receiving treatment with fibrates; (3) HDL cholesterol < 40 mg/dL in men and < 50 mg/dL in women or receiving treatment with statins; (4) fasting glucose ≥ 100 mg/dL; and (5) BP ≥ 130/85 mmHg or receiving treatment with antihypertensive drugs[30]. Plasma adiponectin concentrations were determined using a MILLIPLEX MAP Human Adipokine Magnetic Bead Panel 1 kit (Millipore, Billerica, MA). The coefficient of variability for intra- and inter-assay precision were 7.3% and 8.1%, respectively.

**Definition of clinical outcomes**

The primary endpoint was all-cause mortality and composite renal outcomes (ESRD or 50% reduction in eGFR from baseline). All-cause mortality was determined through death certificates and the National Death Index. ESRD was defined as a history of renal replacement therapy (RRT) (commencement of hemodialysis, peritoneal dialysis, or renal transplantation), which was ascertained using catastrophic illness cards issued by the Bureau of National Health Insurance. For patients who reached the renal endpoint, their eGFR data were collected until dialysis initiation. Other patients periodically received follow-up until June 30, 2017, and during follow-up, they underwent serial blood examination and evaluation of CKD complications.

**Statistical analysis**

Descriptive statistics are summarized as frequency and percentage for categorical data, as means ± standard deviation (SD) for continuous variables with normal distributions, and as median with interquartile range (25th–75th percentile) for non-normally distributed data. Normal distribution was tested using the Kolmogorov–Smirnov test. Between-group comparisons were achieved by chi-square test for categorical variables, the t-test for normally distributed continuous variables, and the Mann-Whitney U test for variables with non-normal distributions. To determine the variables which were independently predictive of adiponectin levels, multivariable linear regression analysis was employed including five metabolic indicators.
Logarithmic transformation of variables with a skewed distribution (TG, UPCR, and CRP) was applied in analysis. The multivariate Cox proportional hazards model was used to assess the association of baseline variables with clinical outcome risks through estimating the hazard ratio (HR) and corresponding 95% confidence interval (CI) of each predictor. Sequential models were established with three incremental levels of covariates: (1) unadjusted analysis; (2) model 1 was adjusted for age, sex, gout history, and BMI; (3) model 2 was adjusted for model 1 covariates as well as metabolic syndrome components; and (4) model 3 was adjusted for model 2 variables, as well as other laboratory potential confounders such as albumin, hemoglobin (Hb), CRP, eGFR, and UPCR, which were selected based on previous publications and clinical relevance. We subsequently conducted subgroup analyses stratified by age (≥65 vs <65 years), sex, eGFR (≥25 vs <25 mL/min/1.73 m²), UPCR (≥0.5 vs <0.5 g/gCr), albumin (≥4.2 vs <4.2 mg/dL), BMI (≥25 vs <25 kg/m²), and metabolic syndrome components. After adjusting for all possible confounders, interactions of the variables with adiponectin were evaluated through the addition of interaction terms. The trend for the mean adiponectin level among patients with varying numbers of metabolic syndrome components was also verified. A P value of <0.05 was considered significant. All statistical analyses were conducted using IBM SPSS Statistics for Windows version 22.0 (IBM SPSS Inc., Chicago, IL, USA).

Results

Participant characteristics

Table 1 summarizes the baseline characteristics of 196 patients stratified into two groups based on the presence of metabolic syndrome. This cohort had a mean age of 65.3 ±13.6 years and mean eGFR of 29.8 ±12.8 mL/min/1.73 m², and 66.3% of the study population was male. The median baseline adiponectin level was 29.4 (interquartile range, 13.3–108.7) μg/mL. Patients with metabolic syndrome had a significantly higher prevalence of gout and HTN as well as higher BMI, waist circumference, Hb, HDL, and TG levels. During the mean follow-up period of 5 years (66.5 ±17.7 months), 48 (24.5%) incident cases of ESRD were observed and 33 (16.8%) deaths occurred. In the analysis of the association of adiponectin with metabolic factors, the adiponectin concentration decreased progressively with increasing numbers of metabolic syndrome components (P for trend = 0.03).

Regarding sex differences in adiponectin level have been established in published studies [31–33], our cohort showed that adiponectin was higher (P = 0.03) in female patients (97.2 ±132.5 μg/mL) than in male patients (62.2±88.0 μg/mL). In addition, we separately evaluated correlation between adiponectin and adiposity covariates (BMI and waist circumference) according to sex. The unadjusted adiponectin level was strongly and inversely correlated with BMI (r = -0.29; P < 0.001) and waist circumference (r = -0.35; P < 0.001; Fig 1A and 1B) to a similar extent among both male and female patients.

Relationship between clinical and biochemical variables and log-transformed adiponectin

Table 2 shows the result of multivariable linear regression of relevant clinical and biochemical covariates with log-transformed adiponectin as the dependent variable. However, collinearity between BMI and waist circumference was detected by Spearman rank correlation (r = 0.841; P < 0.001); formal testing showed a tolerance value (variance inflation factor) of 4.617. Therefore, we evaluated the linear regression in a separate model including different adiposity index (waist circumference or BMI). In the fully adjusted model, log-transformed adiponectin had a
significantly negative relationship with waist circumference ($\beta = -0.015; P < 0.001$), BMI ($\beta = -0.020; P < 0.04$), MBP ($\beta = 0.007; P = 0.01$), HDL ($\beta = 0.007; P = 0.03$), and eGFR ($\beta = -0.011; P = 0.002$). The $R^2$ value of the goodness-of-fit of this adjusted model was 0.27.
Fig 1. Correlations of adiponectin with adiposity index. (A) Correlations of adiponectin with BMI (B) Correlations of adiponectin with waist circumference.

https://doi.org/10.1371/journal.pone.0220158.g001
Multivariable Cox proportional hazard regression analysis was used to examine whether adiponectin is independently associated with clinical outcome risks (Table 3). In the unadjusted model, the HRs for each one-unit increase in the log-transformed adiponectin level (continuous variable) were 1.98 (95% CI, 1.17–3.39; \( P = 0.01 \)) for RRT and 1.77 (95% CI, 1.19–2.63; \( P = 0.005 \)) for composite renal outcomes. The estimates for log-transformed adiponectin became stronger with increment adjustment for demographic factors, BMI, and singular

### Table 2. Multivariable linear regression for determinants of adiponectin levels (log transformed).

| Variables          | \( \beta \)   | 95% CI      | \( p \)-value |
|--------------------|---------------|-------------|---------------|
| Age (years)        | 0.005         | 0.000 to 0.011 | 0.051         |
| Male vs. female    | 0.096         | -0.066 to 0.259 | 0.244         |
| Waist circumference (cm) | -0.015     | -0.022 to -0.007 | <0.001       |
| MBP                | 0.007         | 0.002 to 0.012 | 0.011         |
| AG sugar           | -0.002        | -0.008 to 0.004 | 0.508         |
| HDL                | 0.007         | 0.001 to 0.012 | 0.026         |
| Log TG             | -0.115        | -0.459 to 0.228 | 0.503         |
| Albumin            | -0.096        | -0.314 to 0.121 | 0.385         |
| Hb                 | -0.037        | -0.080 to 0.005 | 0.084         |
| Log CRP            | -0.006        | -0.125 to 0.114 | 0.927         |
| eGFR (10 ml/min/1.73 m\(^2\)) | -0.113     | -0.185 to -0.041 | 0.002         |
| Log UPCR           | -0.120        | -0.268 to 0.029 | 0.113         |
| Adiposity index*   |              |             |               |
| Waist circumference | -0.015       | -0.022 to -0.007 | <0.001       |
| Or BMI             | -0.020        | -0.039 to -0.001 | 0.040         |

* Linear regression in separate model including different adiposity index

Abbreviations are the same as in Table 1.

https://doi.org/10.1371/journal.pone.0220158.t002

### Adiponectin concentration and its relationship with clinical outcomes

Multivariable Cox proportional hazard regression analysis was used to examine whether adiponectin is independently associated with clinical outcome risks (Table 3). In the unadjusted model, the HRs for each one-unit increase in the log-transformed adiponectin level (continuous variable) were 1.98 (95% CI, 1.17–3.39; \( P = 0.01 \)) for RRT and 1.77 (95% CI, 1.19–2.63; \( P = 0.005 \)) for composite renal outcomes. The estimates for log-transformed adiponectin became stronger with increment adjustment for demographic factors, BMI, and singular

### Table 3. Baseline adiponectin level (continuous variable, log transformed) and outcomes.

|                      | RRT                  | Composite renal outcome | All-cause mortality |
|----------------------|----------------------|-------------------------|---------------------|
|                      | HR (95%CI)\(^a\)     | \( P \)            | HR (95%CI)\(^a\)     | \( P \)            | HR (95%CI)\(^a\)     | \( P \)            |
| Unadjusted           | 1.98 (1.17–3.39)     | 0.01                    | 1.77 (1.19–2.63)     | 0.005              | 1.98 (1.05–3.72)     | 0.04              |
| Adjusted             |                      |                         |                     |                    |                     |                   |
| Model 1\(^b\)        | 1.94 (1.10–3.43)     | 0.02                    | 1.69 (1.11–2.59)     | 0.02               | 1.10 (0.53–2.27)     | 0.80               |
| Model 2\(^c\)        | 2.08 (1.17–3.72)     | 0.01                    | 1.78 (1.15–2.75)     | 0.01               | 1.04 (0.49–2.22)     | 0.91               |
| Model 3\(^d\)        | 2.08 (1.08–4.02)     | 0.03                    | 1.66 (1.03–2.65)     | 0.04               | 0.93 (0.41–2.10)     | 0.86               |

\(^a\) Per unit increase in log-transformed adiponectin
\(^b\) Adjusted for age, gender, BMI, gout
\(^c\) Adjusted for model 1 covariates plus metabolic syndrome criteria: (1) central obesity (waist circumference \( \geq 90 \) cm in men or \( \geq 80 \) cm in women, according to the ethnic criteria for Asians); (2) TG \( \geq 150 \) mg/dL; (3) HDL cholesterol \(< 40 \) mg/dL in men and \(< 50 \) mg/dL in women; (4) fasting glucose \( \geq 100 \) mg/dL or previously diagnosed with type 2 DM; (5) BP \( \geq 130/85 \) mmHg or on treatment for hypertension
\(^d\) Adjusted for model 2 covariates plus Hb, Albumin, CRP, eGFR, UPCR

Values expressed as hazard ratios (HR) and 95% confidence interval (CI).

https://doi.org/10.1371/journal.pone.0220158.t003
components of metabolic syndrome in models 1 and 2. With full adjustment (model 3) for laboratory parameters specific to ESRD (albumin, Hb, CRP, eGFR, and UCPR), the significant association of increasing adiponectin with renal outcome risks remained unchanged: HRs of 2.08 (95% CI, 1.08–4.02; \( P = 0.03 \)) for RRT and 1.66 (95% CI, 1.03–2.65; \( P = 0.04 \)) for composite renal outcome. Although the association between adiponectin and all-cause mortality reached significance in the unadjusted model (\( P = 0.04 \)), the association disappeared after additional adjustment for variables.

We did not explore significant effect modification of the association between adiponectin and composite renal outcome in different subgroups (Fig 2), including age, sex, eGFR, UPCR, albumin, BMI and presence of metabolic syndrome (\( P \) for interaction = 0.33, 0.87, 0.51, 0.32, 0.08, 0.30, and 0.59, respectively). Even for the interaction of singular criteria of metabolic syndrome, the result revealed nonsignificant.

**Discussion**

In the present cohort of patients with non-diabetic CKD, the high adiponectin level was markedly associated with an increased risk of renal outcomes independent of BMI, metabolic syndrome, and conventional CKD risk factors. This finding remained consistent within subgroups of age, sex, metabolic syndrome, BMI, albumin, proteinuria, and eGFR status. In addition, higher adiponectin levels were correlated with lower BMI, waist circumference, and eGFR, which confirmed previously reported data in CKD patients[9, 10, 16, 18].

Adiponectin exists in the plasma as three major complexes: a low-molecular-weight trimer, a middle-molecular-weight hexamer, and a high-molecular-weight (HMW) isoform. Adiponectin activates AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor (PPAR)-\( \alpha \) pathways which mediate its beneficial effect on insulin sensitivity via two major receptors (AdipoR1 and AdipoR2) [34]. Regarding its anti-inflammatory role, adiponectin suppresses macrophage function[35], inhibits the nuclear factor \( \kappa B \) (NF-\( \kappa B \)) pathway [36], interferes endothelial adhesion molecules[37], and induces the expression of anti-inflammatory cytokines[38]. Adiponectin levels are mainly determined by the abdominal visceral fat mass, with an inverse proportion found between them[39]. Obesity decreases both circulating
adiponectin levels and adiponectin receptor expression, resulting in the reduction of down-stream signaling[40]. Similar to the correlation found in the populations without CKD, our study indicated significant negative correlations between two adiposity surrogates (BMI and waist circumference) in CKD patients, which is in agreement with previous reports. Both BMI and waist circumference can predict abdominal adiposity in CKD patients [41]. Yoon et al. investigated obesity-linked metabolic dysregulation and showed that hypoadiponectinemia is independently associated with the presence of metabolic syndrome in CKD patients, which is definite evidence of the relationship of adiponectin with kidney function[10]. In the present study, we found that the adiponectin level tended to decrease as the number of metabolic syndrome components increased.

Elevated circulating adiponectin has been found in various stages of CKD and in maintenance dialysis. Adiponectin is negatively related to eGFR across mild to advanced CKD[16, 18]. Our study showed fairly consistent findings in multivariate analysis. Based on available knowledge, there are several potential explanations for the negative correlation. First, urinary adiponectin clearance diminishes accompanied with kidney dysfunction, as urinary adiponectin levels are inversely correlated with GFR[42]. The HMW adiponectin isoform, rather than the LMW isoform, has been reported to be a more biologically active component and is accumulated in ESRD[43, 44]. Second, the expression of adiponectin mRNA and AdipoR1 is upregulated in visceral and subcutaneous fat tissue in ESRD patients despite concomitant elevated circulating adiponectin levels[45]. Moreover, postreceptor block in adiponectin receptor signaling has been found[46]. All these findings imply that when kidney function deteriorates, the paradoxical increase in adiponectin may be attributed to the resistance effect of adiponectin rather than only being a reflection of decreased renal elimination. Third, adiponectin rise may represent a compensatory response to counteract chronic inflammation and atherosclerosis, which both characterize CKD status. In addition, the existence of insulin resistance even in early CKD stages may result in an adaptive response to the altered metabolic profiles in terms of elevated adiponectin[15, 47]. Fourth, enhanced production of adiponectin in CKD may also reflect a physiologic response for mitigating kidney injury. In human renal tubular cells, adiponectin has been found to attenuate the adverse effects of angiotensin II by inhibiting NADPH oxidase, NF-κB activity, and fibronectin expression[48]. However, clinical studies have indicated the relationship between adiponectin and albuminuria has a biphasic pattern[49], with a positive association detected in more advanced albuminuria[50]. Therefore, elevated adiponectin might be a beneficial compensatory mechanism to protect against renal injury.

The clinical implications of adiponectin are more complex in CKD. Contrary to the favorable anti-inflammatory, insulin-sensitizing, and cardioprotective effects of adiponectin in healthy subjects, varying results have been obtained for the association between adiponectin and adverse outcomes in CKD. Several studies have indicated an inverse association that a high, rather than a low, adiponectin level predicts adverse CV outcomes and all-cause mortality in CKD[6, 21, 22], and this association is attenuated in ESRD. Zoccali et al. did not find any relationship between high adiponectin and increased mortality in HD patients[31]. Similarly, Dreschler et al. found no association of adiponectin with all-cause mortality in the largest HD cohort to date[25]. In addition, although adiposity might be an important modifier of adverse outcomes in CKD[7, 23], Rhee et al. supported that higher adiponectin remained associated with mortality in HD patients even under comprehensive adjustment for body anthropometry[6]. Therefore, in addition to adiposity, the consequences of persistent inflammation and malnutrition might be implicated in the mechanism through which high adiponectin promotes poor outcomes and eGFR decline. In our study, adiponectin failed to predict overall mortality. The result suggested that multiple biological pathways of adiponectin and differences in
statistical adjustment or population characteristics, including age, sex, comorbidity, inflammation and nutritional status, or disease severity might involve in the result.

There is limited and conflicting evidence for the association of adiponectin with kidney outcomes. Using the MDRD database, Menon et al. did not reveal a direct correlation between adiponectin and the risk of kidney failure among 820 patients with GFR ranging between 13 and 55 mL/min/1.73 m² (mean GFR 33 ± 12 mL/min/1.73 m²) [21]. Conversely, Kollerits et al. identified that high adiponectin predicted CKD progression in men but not in women among 177 non-diabetic patients with mild to moderate CKD (mean GFR 64 ± 39 mL/min/1.73 m²) [19]. Even in type 1 diabetes, adiponectin was an independent risk factor for progression from macroalbuminuria to ESRD, irrespective of HbA1c or eGFR status [51]. Although the eGFR of our patients (29.8 ± 12.8 mL/min/1.73 m²) was similar to that of patients in the MDRD study, our findings are in contrast with theirs. The potential reasons for the discrepancy might be that our patients were older and relatively non-obese (median BMI 23.6 kg/m²), which perhaps highlighted aggravating PEW and inflammatory status in our patients. On the other hand, we also found that the association between adiponectin and ESRD risk was not modified by BMI or metabolic syndrome components. This finding particularly suggests that weight loss or adiposity cannot fully account for poor outcomes. BMI reflects not only fat mass but also muscle mass; the negative relationship of BMI with adiponectin raises the possibility of PEW in higher adiponectin, as previously reported [9]. Indeed, both chronic inflammation and PEW are important determinants of CKD outcomes. Moreover, we did not find sex differences for CKD progression as the study reported by Kollerits et al., which BMI was used for metabolic syndrome diagnosis instead of waist circumference and women with metabolic syndrome was less frequent though [19]. Our study is the first to establish the association of adiponectin with renal outcomes in a comprehensive analysis including metabolic syndrome components, and the results were consistent in different subgroups.

Our study has several limitations that should be acknowledged. First, we did not measure serial adiponectin levels during follow-up, and the isoforms of adiponectin were not differentiated, as the HWM isoform has been reported to be the most biologically active form. Second, apart from BMI and albumin, nutritional indices, such as muscle mass and dietary intake indicators, were not fully included to evaluate PEW status. Therefore, inadequate adjustment of malnutrition markers for the outcome may contribute to residual confounding. Third, the sample size of 65 female patients was relatively small (33.5%) compared with the sample size of male patients. Imbalance in the groups might be likely to interpret the loss of sex-specific associations in the present study.

In conclusion, our study revealed higher adiponectin was associated with a higher risk of ESRD, independent of various ESRD-related variables, including BMI and metabolic syndrome components. In addition, adiponectin was closely correlated with BMI and metabolic syndrome components. Future larger studies are warranted to elucidate the exact predictive effects of adiponectin, particularly different isoforms, among the CKD population in analyses including relevant risk factors.

**Author Contributions**

**Conceptualization:** I-Ching Kuo, Chi-Chih Hung.

**Data curation:** I-Ching Kuo, Ping-Hsun Wu, Hugo You-Hsien Lin, Sheng-Wen Niu, Jiun-Chi Huang.

**Formal analysis:** I-Ching Kuo.

**Methodology:** I-Ching Kuo, Chi-Chih Hung, Yi-Wen Chiu.
Supervision: Chi-Chih Hung, Yi-Wen Chiu, Hung-Chun Chen.
Validation: Hung-Chun Chen.
Writing – original draft: I-Ching Kuo.
Writing – review & editing: Chi-Chih Hung, Yi-Wen Chiu.

References

1. Ohashi K, Ouchi N, Matsuzawa Y. Anti-inflammatory and anti-atherogenic properties of adiponectin. Biochimie. 2012; 94(10):2137–42. Epub 2012/06/21. https://doi.org/10.1016/j.biochi.2012.06.008 PMID: 22713764.

2. Ebrahimi-Mamaeghani M, Mohammadi S, Arehosseini SR, Fallah P, Bazl Z. Adiponectin as a potential biomarker of vascular disease. Vascular health and risk management. 2015; 11:55–70. Epub 2015/02/06. https://doi.org/10.2147/VHRM.S48753 PMID: 25653535; PubMed Central PMCID: PMC4303398.

3. Nigro E, Scurciero O, Monaco ML, Palmieri A, Mazzarella G, Costagliola C, et al. New insight into adiponectin role in obesity and obesity-related diseases. BioMed research international. 2014; 2014:658913. Epub 2014/08/12. https://doi.org/10.1155/2014/658913 PMID: 25110685; PubMed Central PMCID: PMC4109424.

4. Matsuura M, Shimomura I. Roles of adiponectin and oxidative stress in obesity-associated metabolic and cardiovascular diseases. Reviews in endocrine & metabolic disorders. 2014; 15(1):1–10. Epub 2013/09/13. https://doi.org/10.1007/s11154-013-9271-7 PMID: 24026768.

5. Tao L, Gao E, Jiao X, Yuan Y, Li S, Christopher TA, et al. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/hitrative stress. Circulation. 2007; 115(11):1408–16. Epub 2007/03/07. https://doi.org/10.1161/CIRCULATIONAHA.106.666941 PMID: 17339545.

6. Rhue CM, Nguyen DV, Moradi H, Brunelli SM, Dukkipati R, Jing J, et al. Association of Adiponectin With Body Composition and Mortality in Hemodialysis Patients. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2015; 66(2):313–21. Epub 2015/04/01. https://doi.org/10.1053/j.ajkd.2015.02.325 PMID: 25824125; PubMed Central PMCID: PMC4516594.

7. Zoccali C, Postorino M, Marino C, Pizzino P, Tripepi G. Waist circumference modifies the relationship between the adipose tissue cytokines leptin and adiponectin and all-cause and cardiovascular mortality in haemodialysis patients. Journal of internal medicine. 2011; 269(2):172–81. Epub 2010/12/09. https://doi.org/10.1111/j.1365-2796.2010.02288.x PMID: 21138492.

8. Delgado C, Chertow GM, Kaysen GA, Dalrymple LS, Kornak J, Grimes B, et al. Associations of Body Mass Index and Body Fat With Markers of Inflammation and Nutrition Among Patients Receiving Hemodialysis. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2017; 70(6):817–25. Epub 2017/09/06. https://doi.org/10.1053/j.ajkd.2017.06.028 PMID: 28870376.

9. Hyun YY, Lee KB, Oh KH, Ahn C, Park SK, Chae DW, et al. Serum adiponectin and protein-energy wasting in predialysis chronic kidney disease. Nutrition (Burbank, Los Angeles County, Calif). 2017; 33:254–60. Epub 2016/10/04. https://doi.org/10.1016/j.nut.2016.06.014 PMID: 27692989.

10. Yoon CY, Kim YL, Han SH, Yoo TH, Sung SA, Chung WK, et al. Hypoadiponectinemia and the presence of metabolic syndrome in patients with chronic kidney disease: results from the KNOW-CKD study. Diabetology & metabolic syndrome. 2016; 8:75. Epub 2016/11/30. https://doi.org/10.1186/s13098-016-0191-z PMID: 27895721; PubMed Central PMCID: PMC5109641.

11. Shand BI, Scott RS, Elder PA, George PM. Plasma adiponectin in overweight, nondiabetic individuals with or without insulin resistance. Diabetes, obesity & metabolism. 2003; 5(5):349–53. Epub 2003/08/28. PMID: 12940874.

12. Mohan V, Deepa R, Pradeepa R, Vinodkumar S, Mohan M, Velumurugan K, et al. Association of low adiponectin levels with the metabolic syndrome—the Chennai Urban Rural Epidemiology Study (CURES-4). Metabolism: clinical and experimental. 2005; 54(4):476–81. Epub 2005/03/31. https://doi.org/10.1016/j.metabol.2004.10.016 PMID: 15798954.

13. Huang JW, Yen CJ, Chiang HW, Hung KY, Tsai TJ, Wu KD. Adiponectin in peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal function. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2004; 43(6):1047–55. Epub 2004/05/29. PMID: 15168385.
15. Becker B, Kronenberg F, Kiessel JT, Haller H, Morath C, Ritz E, et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. Journal of the American Society of Nephrology: JASN. 2005; 16(4):1091–8. Epub 2005/03/04. https://doi.org/10.1681/ASN.2004090742 PMID: 15743998.

16. Nanayakkara PW, Le Poole CY, Fouque D, van Gulden C, Stehouwer CD, Smulders YM, et al. Plasma adiponectin concentration has an inverse and a non linear association with estimated glomerular filtration rate in patients with K/DQI 3–5 chronic kidney disease. Clinical nephrology. 2009; 72(1):21–30. Epub 2009/07/31. https://doi.org/10.5414/cnp72021 PMID: 19640384.

17. Mills KT, Hamml L, Alper AB, Miller C, Hudaihed A, Balamuthamy S, et al. Circulating adipocytokines and chronic kidney disease. PLoS one. 2013; 8(10):e76902. Epub 2013/10/12. https://doi.org/10.1371/journal.pone.0076902 PMID: 24116180; PubMed Central PMCID: PMC3792047.

18. Ortega Moreno L, Lamaccia O, Copetti M, Salvermini L, De Bonis C, De Cosmo S, et al. Serum Adiponectin and Glomerular Filtration Rate in Patients with Type 2 Diabetes. PLoS one. 2015; 10(10): e0140631. Epub 2015/10/16. https://doi.org/10.1371/journal.pone.0140631 PMID: 26465607; PubMed Central PMCID: PMC4605700.

19. Kollerits B, Fiser D, Heid IM, Ritz E, Kronenberg F. Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. Kidney international. 2007; 71(2):1279–96. Epub 2007/04/26. https://doi.org/10.1038/sj.ki.5002191 PMID: 17457380.

20. Jorsal A, Tamov L, Frystyk J, Lajer M, Flyvbjerg A, Parving HH, et al. Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabietic nephropathy. Kidney international. 2008; 74(5):649–54. Epub 2008/05/23. https://doi.org/10.1038/ki.2008.201 PMID: 18496510.

21. Menon V, Li L, Wang X, Greene T, Balakrishnan V, Madero M, et al. Adiponectin and mortality in patients with chronic kidney disease. Journal of the American Society of Nephrology: JASN. 2006; 17(9):2599–606. Epub 2006/08/04. https://doi.org/10.1681/ASN.2006040331 PMID: 16885405.

22. Machiba Y, Inaba M, Mori K, Kurajoh M, Nishide K, Norimine K, et al. Paradoxical positive association of serum adiponectin with all-cause mortality based on body composition in Japanese haemodialysers patients. Scientific reports. 2018; 8(1):14699. Epub 2018/10/04. https://doi.org/10.1038/s41598-018-33011-y PMID: 30279489; PubMed Central PMCID: PMC6168594.

23. Tsialgalou C, Chalkias K, Kantartzis K, Tziakas D, Kampouromiti G, Vargemezis V, et al. Differential effect of baseline adiponectin on all-cause mortality in hemodialysis patients depending on initial body mass index. Long-term follow-up data of 4.5 years. Journal of renal nutrition: the official journal of the Council on Renal Nutrition of the National Kidney Foundation. 2013; 23(1):45–56. Epub 2012/03/13. https://doi.org/10.1053/j.jrn.2011.12.007 PMID: 22406123.

24. Aeddula NR, Cheungpasitporn W, Thongprayoon C, Pathireddy S. Epicardial Adipose Tissue and Renal Disease. Journal of clinical medicine. 2019; 8(3). Epub 2019/03/06. https://doi.org/10.3390/jcm8030299 PMID: 30832377; PubMed Central PMCID: PMC6463003.

25. Drechsler C, Krane V, Winkler FW, Wanner C. Changes in adiponectin and the risk of sudden death, stroke, myocardial infarction, and mortality in hemodialysis patients. Kidney international. 2009; 76(5):567–75. Epub 2009/06/12. https://doi.org/10.1038/ki.2009.200 PMID: 19516245.

26. Yun HR, Kim H, Park JT, Chang Tl, Yoo TH, Kang SW, et al. Obesity, Metabolic Abnormality, and Progression of CKD. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2018; 72(3):400–10. Epub 2018/05/08. https://doi.org/10.1053/j.jkd.2018.02.062 PMID: 29728317.

27. Huh JH, Yadav D, Kim JS, Son JW, Choi E, Kim SH, et al. An association of metabolic syndrome and chronic kidney disease from a 10-year prospective cohort study. Metabolism: clinical and experimental. 2017; 67(9):1279–96. Epub 2017/01/14. https://doi.org/10.1016/j.metabol.2016.11.003 PMID: 28081778.

28. Hsu CC, Hwang SJ, Wen CP, Chang HY, Chen T, Shiu RS, et al. High prevalence and low awareness of CKD in Taiwan: a study on the relationship between serum creatinine and awareness from a nationally representative survey. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2006; 48(5):727–38. Epub 2006/10/25. https://doi.org/10.1053/j.jkd.2006.07.018 PMID: 17059992.

29. Hwang SJ, Yang WC, Lin MY, Mau LW, Chen HC. Impact of the clinical conditions at dialysis initiation on mortality in incident haemodialysis patients: a national cohort study in Taiwan. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association—European Renal Association. 2010; 25(8):2616–24. Epub 2010/06/04. https://doi.org/10.1093/ndt/gfp308 PMID: 20519231.

30. Liu J, Grundy SM, Wang W, Smith SC Jr., Vega GL, Wu Z, et al. Ethnic-specific criteria for the metabolic syndrome: evidence from China. Diabetes care. 2006; 29(6):1414–6. Epub 2006/05/30. https://doi.org/10.2337/dcm06-0481 PMID: 16732037.
31. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. Journal of the American Society of Nephrology: JASN. 2002; 13(1):134–41. Epub 2001/12/26. PMID: 11752030.

32. Guebre-Egziabher F, Bernhard J, Funahashi T, Hadj-Aissa A, Fouque D. Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association—European Renal Association. 2005; 20(1):129–34. Epub 2004/12/09. https://doi.org/10.1093/ndt/gfi568 PMID: 15585515.

33. Wang J, Li H, Franco OH, Yu Z, Liu Y, Lin X. Adiponectin and metabolic syndrome in middle-aged and elderly Chinese. Obesity (Silver Spring, Md). 2008; 16(1):172–8. Epub 2008/01/29. https://doi.org/10.1093/oby/doi007.2007.42 PMID: 18223631.

34. Zha D, Wu X, Gao P. Adiponectin and Its Receptors in Diabetic Kidney Disease: Molecular Mechanisms and Clinical Potential. Endocrinology. 2017; 158(7):2022–34. Epub 2017/04/13. https://doi.org/10.1210/en.2016-1765 PMID: 28402446.

35. Ouchi N, Kihara S, Arita Y, Matsuyama A, Okamoto Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation. 2001; 103(8):1057–63. Epub 2001/02/27. https://doi.org/10.1161/01.cir.103.8.1057 PMID: 11224666.

36. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation. 2000; 102(11):1296–301. Epub 2000/09/12. https://doi.org/10.1161/01.cir.102.11.1296 PMID: 10982546.

37. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999; 100(25):2473–6. Epub 1999/12/22. https://doi.org/10.1161/01.cir.100.25.2473 PMID: 10604883.

38. Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochemical and biophysical research communications. 2004; 323(2):630–5. Epub 2004/09/17. https://doi.org/10.1016/j.bbrc.2004.08.145 PMID: 15369797.

39. Crop M, Havel PJ, Utschneider KM, Carr DB, Sinha MK, Boyko EJ, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia. 2003; 46(4):459–69. Epub 2003/04/11. https://doi.org/10.1007/s00125-003-1074-z PMID: 12687327.

40. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponec tin and adiponec tin receptors in insulin resistance, diabetes, and the metabolic syndrome. The Journal of clinical investigation. 2006; 116(7):1784–92. Epub 2006/07/11. https://doi.org/10.1172/JCI29126 PMID: 16823476; PubMed Central PMCID: PMC1483172.

41. Sanches FM, Avesani CM, Kamimura MA, Lemos MM, Axelsson J, Vasselati P, et al. Waist circumference and visceral fat in CKD: a cross-sectional study. American journal of medicine sciences: the official journal of the National Kidney Foundation. 2008; 52(1):66–73. Epub 2008/04/29. https://doi.org/10.1053/j.amjdis.2008.02.004 PMID: 18440683.

42. Yaturu S, Reddy RD, Rains J, Jain SK. Plasma and urine levels of resistin and adiponectin in chronic kidney disease. Cytokine. 2007; 37(1):1–5. Epub 2007/03/27. https://doi.org/10.1016/j.cyto.2007.02.003 PMID: 17383891.

43. Shen YY, Charlesworth JA, Kelly JJ, Lui KW, Peake PW. Up-regulation of adiponectin, its isoforms and receptors in end-stage kidney disease. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association—European Renal Association. 2007; 22(1):171–8. Epub 2006/09/29. https://doi.org/10.1093/ndt/gfl552 PMID: 17005524.

44. Komaba H, Igaki N, Goto S, Yokota K, Doi H, Takemoto T, et al. Increased serum high-molecular-weight complex of adiponectin in type 2 diabetic patients with impaired renal function. American journal of nephrology. 2006; 26(5):476–82. Epub 2006/11/11. https://doi.org/10.1159/000096870 PMID: 17095862.

45. Martinez Cantarin MP, Waldman SA, Doria C, Frank AM, Maley WR, Ramirez CB, et al. The adipose tissue production of adiponectin is increased in end-stage renal disease. Kidney international. 2013; 83(3):487–94. Epub 2013/01/04. https://doi.org/10.1038/ki.2012.421 PMID: 23283133; PubMed Central PMCID: PMC3587362.

46. Martinez Cantarin MP, Keith SW, Waldman SA, Falkner B. Adiponectin receptor and adiponectin signaling in human tissue among patients with end-stage renal disease. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association—European Renal Association. 2014; 29(12):2268–77. Epub 2014/07/23. https://doi.org/10.1093/ndt/gfu246 PMID: 25049200; PubMed Central PMCID: PMC4240178.
47. Nerpin E, Riserus U, Ingelsson E, Sundstrom J, Jobs M, Larsson A, et al. Insulin sensitivity measured with euglycemic clamp is independently associated with glomerular filtration rate in a community-based cohort. Diabetes care. 2008; 31(8):1550–5. Epub 2008/05/30. https://doi.org/10.2337/dc08-0369 PMID: 18509205; PubMed Central PMCID: PMC2494665.

48. Fang F, Liu GC, Kim C, Yassa R, Zhou J, Scholey JW. Adiponectin attenuates angiotensin II-induced oxidative stress in renal tubular cells through AMPK and cAMP-Epac signal transduction pathways. American journal of physiology Renal physiology. 2013; 304(11):F1366–74. Epub 2013/03/29. https://doi.org/10.1152/ajprenal.00137.2012 PMID: 23535586.

49. Christou GA, Kiortsis DN. The role of adiponectin in renal physiology and development of albuminuria. The Journal of endocrinology. 2014; 221(2):R49–61. Epub 2014/01/28. https://doi.org/10.1530/JOE-13-0578 PMID: 24464020.

50. Kim HY, Bae EH, Ma SK, Chae DW, Choi KH, Kim YS, et al. Association of serum adiponectin level with albuminuria in chronic kidney disease patients. Clinical and experimental nephrology. 2016; 20(3):443–9. Epub 2015/10/09. https://doi.org/10.1007/s10157-015-1173-4 PMID: 26445954.

51. Saraheimo M, Forsblom C, Thom L, Waden J, Rosengard-Barlund M, Heikkila O, et al. Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes. Diabetes care. 2008; 31(6):1165–9. Epub 2008/03/19. https://doi.org/10.2337/dc07-2306 PMID: 18346990.